One of the challenges in developing cell lines for high-throughput screening in drug discovery is the labor-and timeintensive process required to create stable clonal cell lines that express specific reporters or drug targets. The authors report here the generation of a site-specific retargeting platform in 3 different cell lines: adherent HEK293, suspension CHO-S, and a human embryonic cell line (BGO1V). These platform cell lines were generated by using a combination of 2 site-specific integrases to develop a system that allows one to efficiently target a gene of interest to a specific locus and generates rapid production of homogeneous cell pools that stably express the gene of interest. The phiC31 integrase was used to create a platform line by placing a target site for the R4 integrase into a pseudo attP site, and then the R4 integrase was used to place a gene of interest into specific R4 target site. The authors demonstrate the successful and rapid retargeting of a G-proteincoupled receptor (cholecystokinin receptor A, CCKAR), an ion channel (the transient receptor potential cation channel, subfamily M, member 8, TRPM8), and a GFP-c-Jun(1-79) fusion protein into the specific loci in these cell lines and show that these retargeted cell lines exhibit functional and pharmacological responses consistent with those reported in the literature. (Journal of Biomolecular
INTRODUCTION
T oday, both Chinese hamster ovary (CHO) and human embryonic kidney (HEK293) cells are among the most prominent mammalian cell lines for protein production and highthroughput screening (HTS) of drug targets. [1] [2] [3] However, as more relevant physiological cell models are desired, embryonic stem cells and primary cells are likely to play important roles as cell models in drug discovery. 4, 5 Theoretically, embryonic stem cells can provide an inexhaustible source of various types of precursor cells and can serve as a platform for target identification and validation, lead identification and optimization, safety pharmacology, metabolic profiling, and toxicology. However, to fulfill their potential in this field, there needs to be a way to efficiently engineer these cell types to express 1 or more reporter(s) or target(s), to enable a measurable readout in response to specific stimuli. In most cases, this process requires the generation of stable cell lines, typically clonal in nature, which is time and labor intensive.
The most common method used to generate stable cell lines relies on random integration of the gene of interest after transfection of plasmid DNA or transduction with viruses, followed by antibiotic selection of a stable pool of cells and functional screening to identify individual clones that have high expression or correct function. These methods, however, remain inefficient, and the expression level of genes varies greatly over long-term culture due to positional effects. 6 We present here a site-specific integration platform that enables the targeting of a gene of interest to a specific locus at a high efficiency and generation of stable cell lines in a much shorter time than conventional methods. This method effectively eliminates differences in expression of the gene of interest due to genomic position effects and varying copy numbers and increases the likelihood of obtaining isogenic clones. We have used integrases from Streptomyces phages PhiC31 and R4, which have been previously shown to perform unidirectional and irreversible integration of the nucleic acid substrate in a number of cell lines, including human, mouse, rat, Chinese hamsters, and plants. [7] [8] [9] [10] [11] In contrast, other commonly used site-specific recombinases, such as Cre and FLP, catalyze a reversible reaction that can lead to deletion or transgenes being recombined out of the genome after integration. 12, 13 PhiC31 integrase has been shown to target pseudo attP sites present in the genome, which are often in transcriptionally active areas. 7, 11 Therefore, genes inserted in these pseudo attP sites are often expressed at a higher level compared to those inserted at random sites.
In this study, we have taken advantage of the ability of the phiC31 integrase to target well-expressed regions (pseudo attP sites) of the genome to place an acceptor site for the R4 integrase and thereby create R4 platform lines. These platform lines can then be retargeted with R4 integrase to efficiently generate cell lines expressing the gene of interest, and our strategy allows us to expand pools of cells as well as isolate individual colonies. Using this method, we have successfully created cell lines expressing 3 different genes representing a G-protein-coupled receptor (GPCR) receptor (CCKAR), an ion channel receptor (TRPM8), and a transcription factor in the JNK pathway (GFP-c-Jun(1-79)) and shown that it provides significant advantages over existing strategies. We have also successfully developed cell-based assays in human embryonic stem cells using the phiC31/R4 system. In summary, we have demonstrated that the phiC31/R4 cell-engineering system can be used for the rapid development of HTS-capable assays for multiple targets in different cellular backgrounds, including human embryonic stem cells.
MATERIALS AND METHODS

Cell culture and generation of platform cell lines
The CHO-S suspension cell line adapted from CHO-K1 was maintained in CD CHO medium and 8 mM L-glutamine (Invitrogen, Carlsbad, CA). One day before transfection, 15 × 10 6 cells were seeded in 30 mL of CD CHO medium and incubated at 37 °C, 5% CO 2 on a shaker for 24 h. After 24 h, cells were counted and seeded at a density of 1 × 10 6 cells/mL in CD CHO medium. Then, 11 µg of pJTI/NEO plasmid (Invitrogen) and 26 µg of phiC31 integrase (DNA molar ratio of 2.4:1) plasmid were mixed with 37 µL of Freestyle MAX transfection reagent in 1 mL of Opti-MEM  medium and incubated at room temperature (RT) for 10 min. Cells were incubated with the reagent/DNA mix for 48 h and selected with 600 µg/mL of hygromycin B for approximately 3 weeks until a resistant pool was obtained. Single cells were seeded into 96-well plates to isolate individual clones using 2× cloning medium (Invitrogen). Individual clones were expanded in the presence of 600 µg/mL hygromycin B and 8 mM L-glutamine CD OptiCHO medium. After expansion, 7 µg of retargeting plasmid containing the EF1α promoter driving the gene of interest (CCKAR or TRPM8) and 30 µg of R4 integrase, pJTI R4 Int, (DNA molar ratio of 4:1) were incubated with 37 µL of Freestyle MAX transfection reagent in 1 mL of Opti-MEM  I medium for 10 min. After 24 h, the cells were counted and seeded at 1 × 10 6 cells/mL in CD CHO medium. Cells were transfected with DNA for 48 h and selected with 500 µg/mL of neomycin until a resistant pool was obtained. Stable cell pools were tested in functional assays following approximately 21 days of antibiotic selection.
Human embryonic kidney cells (HEK293, Invitrogen) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1× MEM nonessential amino acids (NEAA) and 10% fetal bovine serum (FBS). Plasmid pJTI/BSD was treated with BamHI enzyme to linearize the vector. The cells were transfected with the linearized pJTI/BSD vector and a plasmid encoding the phiC31 integrase using Lipofectamine 2000 transfection reagent according to the manufacturer's protocol. Following the transfection, the cells were selected for 14 days using 200 µg of hygromycin B/mL. Single isolated colonies were picked 12 to 14 days after selection and expanded. Single clones were expanded and retargeted with the appropriate gene of interest (GFP-c-Jun(1-79), CCKAR, or TRPM8) driven by an EF1α promoter and 5 µg of the R4 integrase plasmid, pJTI R4 Int, using Lipofectamine 2000 (Invitrogen). At 24 h after transfection, selection was started with medium containing 10 µg of blasticidin/mL. After ~21 days, the stable cell pools were tested using the appropriate functional assays.
The BGO1V hESC line (YX15) platform cell line was generated with the pJTI/ZEO plasmid and retargeted with the gene of interest and R4 integrase, pJTI R4 Int, as described previously. 6, 14 
Southern blot verification and plasmid rescue
Genomic DNA from individual clones was isolated using DNAzol  Reagent (Invitrogen). Plasmid rescue was performed as described. 14 Southern blots were performed as follows. Genomic DNA (20 µg) from parent clones was digested with BamHI for HEK293 and BGO1V, XbaI, and SpeI for CHO-S R4. Digested DNAs were separated by electrophoresis on a 0.8% agarose gel overnight. The DNA was transferred onto a Nytran SuPerCharge nylon membrane (Schleicher and Schuell, Piscataway, NJ) using a TurboBlotter (Schleicher and Schuell) and probed with a 1.8-kb DNA probe consisting of the hygromycin expression cassette. Southern blots for retargeted clones were done using the same protocol, and the probe used was obtained by amplification of the CCKAR, TRPM8, or GFP-cJun gene to generate a 500-kb fragment probe.
Fluo-4-based calcium imaging
Cells were maintained in culture as described above and plated into 96-well plates the day before assay at a density of 100,000 cells/well. The next day, medium was removed, and the cells were washed once with Hank's balanced salt solution (HBSS) and then loaded with 3 µM fluo-4 AM + 9% (w/v) Pluronic  F-127 (Invitrogen) in HBSS for ~45 min at RT. Cells were washed again with HBSS and maintained in 100 µL of HBSS at room temperature. Assays were performed on a Hamamastu FDSS, and 20 µL of the appropriate agonist was applied at 6× the final intended concentration. CCKAR or TRPM8 activities were tested by the application of the known agonist ligands sulfated cholecystokinin (CCK-8-S) or menthol, respectively (Sigma-Aldrich, St. Louis, MO). Concentrationresponse curves were generated by subtracting the initial baseline fluo-4 fluorescence from the peak response elicited by ligand application and plotting the difference against ligand concentration using GraphPad Prism software (Graphpad Software, La Jolla, CA). These data were then fit with a sigmoidal dose-response curve to determine the EC 50 values for the applied agonists.
Cellular LanthaScreen™ assays
Cellular LanthaScreen assays for phosphoprotein analysis were performed as recently described. 15 Briefly, HEK293 R4 GFP-c-Jun(1-79) or BGO1V R4 GFP-c-Jun(1-79) cells were plated in assay medium (Opti-MEM  I, supplemented with 0.5% FBS) in a white tissue culture-treated 384-well plate at a density of 10,000 cells per well. Following overnight incubation, the cells were treated for 30 min with the indicated concentrations of tumor necrosis factor alpha (TNFα) or anisomycin. The medium was removed by aspiration, and 20 µL of lysis buffer containing terbium-labeled rabbit anti-c-jun (pS73) polyclonal antibody at a concentration of 2 nM was added to each sample. The samples were incubated for 60 min at RT and analyzed in a BMG Pherastar plate reader. Data analysis and curve fitting were performed using GraphPad Prism software.
RESULTS AND DISCUSSION
Generation of site-specific retargeting cell lines
Three different versions of the acceptor plasmid were made, each with a different antibiotic resistance marker distal to the R4 attP to allow one to choose the preferred marker for secondary retargeting (Fig. 1A, B ). Retargeting was accomplished by targeting a plasmid with a gene of interest (CCKAR, TRPM8, or GFP-cjun) containing the complementary R4 attB recombination site placed distal to a constitutive promoter (either CMV or EF1α) and the R4 integrase, which results in recombination between the R4 attB and attP sites. Integration places the constitutive promoter in the donor plasmid proximal to the drug resistance marker in the platform line, resulting in constitutive expression of the drug resistance marker (blasticidin, neomycin, or zeocin) ( Fig. 1B) . We performed PCR to confirm site-specific recombination by amplifying the region between the EF1α promoter and the neomycin-, blasticidin-, or zeocin-resistant gene (data not shown). For CHO-S platform clones, Southern blot analysis was performed on both clones with a probe that recognizes the target gene, showing that each clone had a single copy of the pJTI/NEO plasmid integrated ( Fig. 2A) and most likely integrated into 2 different pseudo-attP sites. For adherent HEK293 cell lines, Southern blot analysis revealed that clone 18.3 had 2 copies of the pJTI/BSD plasmid and clone 16.2 had 3 copies ( Fig. 2B) .
Further retargeting experiments showed that clone 16.2 could not be retargeted as efficiently as clone 18.3 (data not shown). Therefore, we decided to use clone 18.3 to retarget the CCKAR, TRPM8, and GFP-c-Jun(1-79) expression cassettes. For the human embryonic stem cell platform line, we previously characterized a single copy of pJTI/ZEO plasmid integrated to the chromosome 13 locus (clone YX15) 6 and demonstrated that this clone possesses normal hESC morphology; expresses pluripotent markers Oct4, SSEA4, Tra1-60, and Tra 1-80; differentiates efficiently into all 3 germ layers; and has normal karyotype. 6 In the work presented here, we retargeted the GFP-c-Jun(1-79) and CCKAR expression constructs into this line and confirmed sitespecific retargeting by PCR and single-copy integration by Southern blot analysis (Fig. 2C) .
Functional assays using retargeted cell lines
The retargeted CCKAR, TRPM8, and GFP-c-Jun(1-79) constructs were first examined in the context of the platform HEK293 line. Ligand-induced activation of CCKAR and TRPM8 was monitored using the calcium indicator fluo-4, whereas ligand-induced phosphorylation of GFP-c-Jun(1-79) was monitored using the cellular LanthaScreen technology (Invitrogen), as described previously. 15 The retargeted CCKAR HEK293 cell pool was compared to a previously generated clonal CCKAR HEK293 cell line on the same day and the same assay plate. Cells were challenged with the CCK-8-S. Both CCKAR cell lines responded similar to agonist treatment (Fig. 3C) . Generation of the clonal CCKAR cell line required about 3 months and included random integration of the CCKAR gene and antibiotic selection of a stable cell pool. This was followed by functional selection of individual cells (using flow cytometry for single-cell sorting), clonal expansion of the selected cells, functional testing of the clonal cell lines, expansion of the functionally selected clonal cell lines, and final functional and pharmacological validation. Retargeting of the CCKAR gene allowed for generation of a stable cell pool in about 3 weeks that proved to be functionally equivalent to the clonal cell line (Fig. 3C) . Stable pools expressing either the TRPM8 ion channel or the GFP-c-Jun(1-79) fusion protein were also generated in approximately 3 weeks with the platform HEK293 R4 line. The TRPM8-expressing cells were challenged with stereoisomers of menthol. The resulting agonistevoked calcium influx displayed the expected concentration dependence to the 2 stereoisomers of menthol (Fig. 3D) . 16, 17 The GFP-c-Jun(1-79)-expressing cells were challenged with TNFα. 18, 19 Phosphorylation of the GFP-c-Jun(1-79) was quantified by using the LanthaScreen technology ( Fig. 3E) and compared well to the response of a stable clone engineered in a HEK293 cell line generated by random integration (data not shown). The homogeneity of the stable cell pools was tested by blinded isolation of single cells followed by clonal expansion and functional comparison. Responses from the clones were found to be nearly indistinguishable from the parental pool ( Fig. 4A, B) . Interestingly, we also observed that 1 clone, E2, has a different response profile compared to other clones. Because we have not mapped this clone, we do not know if this clone has a different integration site compared to others. We further analyzed 12 other CCKAR clones and found that their profiles were nearly identical to the pool (data not shown), indicating that the pool's profile represents the majority of the clones. Responses from the TRPM8 clones were nearly identical for 9 of the 12 clones examined, whereas 3 exhibited reduced assay windows. Three GFP-c-Jun(1-79) clones were tested, and all of them exhibited functional responses to TNFα stimulation that were equivalent to the cell pool (data not shown). As shown in Figure 4C , D, the CCKAR and TRPM8 pools generated using site-specific integration were extremely stable. These pools showed unchanged assay window and agonist pharmacology after 37 passages (approximately 4 months) in culture. These data provide compelling evidence that integration of the gene at the retargeted site can provide a stable pool of cells that exhibit stable and homogeneous functional behavior.
To test the portability of this platform system, we next retargeted the CCKAR and TRPM8 genes into the CHO-S platform line and tested for functional responses as above. The Details of the plasmids can be found at www.invitrogen.com. The expression plasmid containing an EF1α promoter upstream of the R4 attB site, as well as an expression cassette with the gene of interest driven by the EF1α promoter, was used to target the gene of interest into the previously generated specific locus. (B) The strategy used to create the platform lines and retargeting with the gene of interest into a specific locus. Three different cell lines were generated with pJTI/BSD, NEO, or ZEO to generate platform lines. Retargeting with the gene of interest was accomplished by transfecting cells with the expression plasmid and the R4 integrase. Successful retargeting leads to activation of the appropriate drug-resistant gene into that locus.
CCKAR-expressing stable cell pool exhibited the expected pharmacology to CCK-8-S, and the TRPM8-expressing stable cell pool exhibited the expected pharmacology to menthol (Fig. 3A,  B) . 16, 17, 20 Similar to the retargeted HEK293 cells, these pools displayed stable responses over 2 dozen passages (data not shown).
Finally, the ability to target genes in stem cells was tested by introducing the GFP-c-Jun(1-79) and CCKAR genes into the targetable BGO1V platform line. 6 Due to the relatively low transfection efficiencies associated with human embryonic stem cells, single foci were easily isolated during the antibiotic selection following the targeting events. The retargeted GFPc-Jun in the BG01V cell line was submitted for karyotyping, and results showed the parental karyotype (data not shown). These colonies of cells were isolated, expanded, and tested using the same functional assays as described above. Agonistinduced phosphorylation of GFP-c-Jun(1-79) by TNF and anisomycin was tested. The TNF pharmacology displayed by the GFP-c-Jun(1-79)-expressing hESCs showed that the EC 50 values were as expected ( Fig. 3F, G) . 18, 19 The agonist-induced calcium release evoked by CCK-8-S in the CCKAR-expressing stem cells matched the expected profiles (Fig. 3H) .
Generation of cell lines for screening of drug targets or protein production often requires use of cell clones containing stably integrated transgenes. Conventional methods such as random integration can take up to 3 to 6 months and result in random integration of the transgene and variation in the copy number. This can lead to variation in expression profiles between clones due to differences in gene dosage and variable position effects on the function of a specific transgene.
Here we demonstrate a genomic retargeting system that enables transgenes to be targeted to a predetermined locus, thereby limiting the effects of variable position and copy number and allowing stable cell lines to be generated more efficiently and robustly than conventional methods. To accomplish this, we used 2 phage integrases: phiC31, which has been shown to specifically integrate transgenes at pseudo-attP sites in bacterial, (E) Tumor necrosis factor alpha (TNFα) induced phosphorylation of GFP-c-Jun(1-79) in a concentration-dependent manner consistent with previous results. 18, 19 EC 50 for clone 1 was 1103 pg/mL (hill slope 0.9), clone 3 was 664.2 pg/mL (hill slope 1.2), and clone 4 was 490 pg/mL (hill slope 1.3). (F, G) The R4 BGO1V line was retargeted with GFP-c-Jun(1-79) and challenged with (F) TNFα and (G) anisomycin. The EC 50 for TNFα was 3383 pg/mL (hill slope 0.9), lower than expected, but the EC 50 for anisomycin was 1.24E-07 M (hill slope 2.2), in the expected range. 18, 19 (H) The R4 BGO1V line was retargeted with CCKAR and tested in a fluo-4-based calcium mobilization assay. Calcium was released in a concentration-dependent manner that was consistent with expected results with an EC 50 of 4.52E-10 M (hill slope 1.6). 20 All samples were performed in quadruplicates. human, CHO, mouse, or rat genome [9] [10] [11] and the R4 integrase, which targets a specific attP site precisely. As reported previously, phiC31 integrase tends to target regions of chromosomes that are more accessible, such as an open chromatin, which often results in higher gene expression. 10 In addition to preferential placement of the R4 target sites to create a platform line, the specific integration (or retargeting) process using the line yields efficient selection of properly targeted clones. The specificity allows the rapid isolation of highly expressing and homogeneous "clonal pools" in lieu of time-intensive generation and validation of multiple singlecell clones. The application of this recombination technology reduces the time required for the generation of a homogenously expressing cell populations from 3 months to approximately 3 weeks when using immortalized cell lines such as HEK293. Even though the HEK293 platform line harbors 2 copies of the R4 plasmid, we were able to retarget efficiently, and all 3 different retargeted clones exhibited normal EC 50 s. In addition, we The CCK-8-S-induced calcium release from the HEK293 R4 cell pool was similar to the responses induced from blindly isolated clones derived from that pool. The EC 50 for the pool was 3.40E-10 M (hill slope 0.6), EC 50 for clone C8 was 1.93E-10 M (hill slope 0.8), EC 50 for clone D2 was 4.63E-10 M (hill slope 0.6), EC 50 for clone D11 was 1.45E-09 M (hill slope 0.6), and EC 50 for clone H8 was 8.95E-10 M (hill slope 0.8). (B) The (+)-menthol induced calcium influx in the R4 293 TRPM8 cell pool was similar to the responses induced from blindly isolated clones derived from that pool. The EC 50 for the pool was 1.89E-5 M (hill slope 1.7), EC 50 for clone C8 was 2.4E-5 M (hill slope 1.4), EC 50 for clone D5 was 2.14E-5 M (hill slope 1.9), EC 50 for clone D12 was 3.8E-05 M (hill slope 3.4), and EC 50 for clone E2 was 2.87E-5 M (hill slope 1.5). All samples were performed in duplicates. (C, D) Following 4 months in culture and 37 passages, both the (C) CCK-8-S-induced calcium release from the R4 293 CCKAR cell pool with EC 50 of 3.59E-10 M (hill slope 0.7) and clone C8 EC 50 of 4.53E-10 M (hill slope 0.8) and the (D) (+)-menthol-induced calcium influx in the R4 293 TRPM8 cell pool with EC 50 of 1.74E-05 M (hill slope 1.3) and clone D5 EC 50 of 1.58E-05 M (hill slope 1.2) maintained a relatively unchanged assay window and pharmacology. All samples were performed in duplicates.
were able to generate retargeted cell pools displaying similar functional assay performance compared to individual clones, and our data demonstrated that the retargeted cell pools remain functionally unchanged for at least 37 passages. We expect the single-copy clone to behave similar to the 2-copy clone because the phiC31 integrase tends to target "hot" spots (open chromatin regions) at a higher frequency than other sites. We analyzed 2 different sites in the CHO-S lines, and both had similar EC 50 s for 2 different targets. However, we did observe differences in the maximum responses between the 2 clones that could be due to (1) different expression levels of the target placed at one isogenic location versus another, (2) day-to-day assay variability, or (3) variable cell loss, particularly given that these suspension-adapted cells were plated into adherent culture conditions that required medium removal and washes to perform the fluo-4-based calcium imaging experiments. Nevertheless, 2 different targets were integrated at 2 different sites, and both targets exhibit accurate pharmacology.
The use of stem cells for the drug discovery and development process will undoubtedly be in great demand in the near future. Here we also used a human embryonic stem cell platform line (BGO1V), 6 successfully retargeted 2 relevant drug discovery targets into that line, and demonstrated the performance of those retargeted cells in functional assays. We assayed 3 different individual clones and found that they all have identical EC 50 s in our functional assays.
The R4 cell engineering system represents an open platform that has the versatility to support multiple functions. As mentioned above, the insertion event is efficient and specific to particular loci, which makes generation of isogenic cell lines for drug discovery or bioproduction rapid and scalable. Given that specific loci are targeted, consistency of expression is expected across all the cells in the primary pool, facilitating generation of robust assay platforms in a short timeline. Specific targeting also allows generation of an isogenic series of assays that would be expected to carry comparable expression profiles due to their placement in identical genomic and cellular backgrounds. This strategy can provide significant advantages for comparing disease-relevant mutations and single-nucleotide polymorphisms to the wild-type gene as well as for comparing the function of species orthologs at a specific locus to better understand the correlation between animal models and human outcomes. These types of assays are difficult to achieve using current techniques that rely on random integration of the target gene. In addition, using this system, we can map and identify the site where the gene has integrated in the genome. Although we present data only from single-promoter gene combinations in this study, the R4 system is fully capable of delivering multiple expression cassettes to the target locus on a single plasmid.
In conclusion, we described here a system that enables genetic material to be targeted at a specific and predetermined locus and demonstrated the expected protein function in 3 cell lines: CHO-S, HEK293, and hESC/BGO1V. The overall process allows generation of reproducible and high expression clones and pools in a very short timeframe due to the specificity and efficiency of cell engineering and the generation of exp ression constructs via Multisite Gateway technology. Adoption of this technique will allow researchers to assemble multiple reporters and promoters, as well as deliver multiple genetic elements at a specific locus, thereby enhancing the process of stable cell line development for drug screening, bioproduction, and cell-based therapy.
